ENVB - Enveric Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.9500
-0.4900 (-11.04%)
At close: 04:00PM EDT
4.0200 +0.07 (+1.77%)
After hours: 06:55PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Long-term KST

Long-term KST

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close4.4400
Open4.1600
Bid3.9500 x 1300
Ask4.1500 x 1000
Day's Range3.8750 - 4.4300
52 Week Range1.3000 - 18.5000
Volume221,013
Avg. Volume3,527,628
Market Cap8.209M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
EPS (TTM)-10.6700
Earnings DateAug 10, 2023 - Aug 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateApr 23, 2008
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ENVB

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023

    CAMBRIDGE, Mass., May 30, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that research foundational to the development of the Company’s EVM201 Series and EVM301 Series is featured in a poster presentation at the 16th Annual Canadian Neuroscience Meeting (CAN 2023) being held May 28-31, 2023.

  • Business Wire

    Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug

    CAMBRIDGE, Mass., May 24, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving its EVM201 Series. This is the second Notice of Allowance from the USPTO for intellectu

  • Business Wire

    Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders

    CAMBRIDGE, Mass., May 22, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, has announced new research results detailing the development of novel psilocin prodrug derivatives targeting treatment of mental health disorders. A manuscript describing the research has been submitted for peer-reviewed publication and is

  • Business Wire

    Enveric Biosciences to Participate in 2023 BIO International Convention in Boston

    CAMBRIDGE, Mass., May 19, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in this year’s 2023 BIO International Convention, which is being held in Boston, MA, June 5-8, 2023.

  • Business Wire

    Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin

    CAMBRIDGE, Mass., May 18, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application involving EB-373, the Company’s new chemical entity (NCE) psilocin prodrug being developed for th

  • Business Wire

    Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights

    CAMBRIDGE, Mass., May 15, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the first quarter of 2023 ended March 31, 2023.

  • Business Wire

    Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month

    CAMBRIDGE, Mass., May 02, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its support of Mental Health Awareness Month this May as the company advances its novel development programs to improve the treatment of mental health disorders.

  • Business Wire

    Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference

    CAMBRIDGE, Mass., April 10, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will participate in the Benzinga Psychedelics Capital Conference being held Thursday, April 13, 2023, at the Fontainebleau Miami Beach, Florida.

  • Business Wire

    Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results

    CAMBRIDGE, Mass., April 03, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2022.

  • Business Wire

    Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373

    CAMBRIDGE, Mass., March 23, 2023--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has entered into an agreement with Avance Clinical, an Australia-based contract research organization (CRO) with US operations, for its planned Phase 1 clinical trial of EB-373, the company’s lead candidate targeti

  • Business Wire

    Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications

    CAMBRIDGE, Mass., March 21, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that it has established Enveric Therapeutics Pty. Ltd., an Australia-based subsidiary, to support the Company’s plans to advance its EVM201 Series, including lead candidate EB-373, towards the clinic. Enveric Therapeutics will o

  • Business Wire

    Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery

    CAMBRIDGE, Mass., March 14, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today new research detailing the first-ever isolation of a novel indolethylamine N-methyltransferase from cane toad (Rhinella marina) and the successful development of a bioproduction platform for the isolation and pharmacological scr

  • Business Wire

    Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., February 28, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Kevin Coveney, CPA, to the position of Chief Financial Officer, effective March 13, 2023. Mr. Coveney brings 30+ years of accounting, finance, and operations experience to Enveric, having previously served

  • Business Wire

    Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., February 23, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, announced today the appointment of Lynn Gallant to the position of Vice President, Clinical Operations. Ms. Gallant brings more than 25 years of clinical operations and trial management experience to Enveric and will work alongside Bob Daghe

  • Business Wire

    Enveric Biosciences to Present at the Gravitas Securities Inc. 6th Annual Growth Conference

    CAMBRIDGE, Mass., February 22, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that Joseph Tucker, Ph.D., Chief Executive Officer, will present at the Gravitas Securities Inc. 6th Annual Growth Conference being held Thursday, March 2, 2023, at the Fairmont Pacific Rim Hotel in Vancouver, British Columbi

  • Business Wire

    Enveric Biosciences to Present at the BIO CEO & Investor Conference

    CAMBRIDGE, Mass., February 01, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that CEO Joseph Tucker, Ph.D., will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City.

  • Business Wire

    Enveric Biosciences to Present at the 6th Annual Neuroscience Innovation Forum and Biotech Showcase during "J.P. Morgan Health Care Week 2023"

    CAMBRIDGE, Mass., December 21, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, announced today that the company will present at the 6th Annual Neuroscience Forum and the Biotech Showcase™. Both events will be held live and are scheduled to coincide with the 41st Annual J.P. Morgan Health Care Conference in San Francisco

  • Business Wire

    Enveric Biosciences Announces Confidential Submission of Registration Statement for the Spin-off of its Cannabinoid Business to Shareholders

    CAMBRIDGE, Mass., November 28, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the confidential submission of a Form S-1 draft registration statement with the U.S. Securities and Exchange Commission (‘SEC’) for the spin-off its cannabinoid clinical development pipeline to a wholly-owned subsidiary, Akos

  • Business Wire

    Enveric Biosciences to Participate in A.G.P.’s Virtual Biotech Conference

    CAMBRIDGE, Mass., November 16, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Avani Kanubaddi, President & COO of Enveric Biosciences, will participate in A.G.P.’s Virtual Biotech Conference to be held from November 30, 2022 – December 1, 2022.

  • Business Wire

    Enveric Biosciences to Participate in Wonderland: Miami on November 3-5, 2022

    CAMBRIDGE, Mass., November 01, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced that Dr. Joseph Tucker, Chief Executive Officer of Enveric Biosciences, will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Center in Miami, FL on November 3-5, 2022.

  • Business Wire

    Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies

    CAMBRIDGE, Mass., October 24, 2022--Enveric Biosciences Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the nomination of EB-373 as the lead development candidate to emerge from its EVM201 program. EB-373 is under development for the treatment of anxiety disorders.

  • Business Wire

    Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference

    CAMBRIDGE, Mass., October 12, 2022--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression and addiction disorders, today announced the presentation of results from its lead programs at the 6th International Neurology & Brain Disorders Conference (INBC) to be held on October 24-26, 2022, in Orlando, Florida (https://neurologycongress.com). The Company’s pos

  • Business Wire

    Enveric Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

    CAMBRIDGE, Mass., August 31, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Avani Kanubaddi, President & COO of Enveric, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.

  • Business Wire

    Enveric Biosciences Appoints New Independent Directors

    CAMBRIDGE, Mass., July 27, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has appointed three new independent directors, Michael D. Webb, President and CEO of CXL Ophthalmics, Bevin O'Neil, Chief Strategy Officer of ECRI, and Frank Pasqualone, recently retired Chief Business Officer of Theravance, to its Board of Directors.

  • Business Wire

    Enveric Biosciences Announces Closing of $8 Million Registered Direct and Private Placement Offerings, Priced at a Premium to Market Under Nasdaq Rules

    CAMBRIDGE, Mass., July 26, 2022--Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that it has closed its previously announced registered direct offering for the purchase and sale of 375,000 shares of the Company’s common stock (or pre-funded warrants in lieu thereof), priced at a premium to market under Nasdaq rules. In addition, the Company